---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-003905"
form_type: "8-K"
ticker: null
cik: "0001900520"
company_name: "Lomond Therapeutics Holdings, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:43:00.848647+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lomond terminates menin inhibitor license from Bala; receives 3.5% stake

## Summary
- Terminated license agreement with Bala for an early-stage menin inhibitor (AML) due to crowded competitive landscape.
- Company had spent ~$600K on development; $1.2M deferred payment obligation cancelled with termination.
- Received 111,585 shares of Bala common stock (~3.5% of fully diluted cap) as consideration for prior expenditure.
- All licensed IP reverts to Bala; no further development or payments required.
- No activities or third-party agreements had been undertaken under the license.

## SEC filing metadata
- accession: 0001213900-26-003905
- form_type: 8-K
- cik: 0001900520
- company_name: Lomond Therapeutics Holdings, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1900520/000121390026003905/0001213900-26-003905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1900520/000121390026003905/ea0269967-8k_lomond.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-003905
- JSON: https://secwatch.observer/filing/0001213900-26-003905.json
- Plain text: https://secwatch.observer/filing/0001213900-26-003905.txt

## Key facts
- Material Agreements
  Lomond Therapeutics Holdings, Inc. terminated License Agreement with Bala Therapeutics, Inc. valued at Terminated agreement with consideration including shares representing 3.5% fully diluted capitalizat (effective 2026-01-07).
  - Action: termination
  - Agreement: license
  - Counterparty: Bala Therapeutics, Inc.
  - Value: Terminated agreement with consideration including shares representing 3.5% fully diluted capitalizat
  - Effective: 2026-01-07
  source text: On January 7, 2026, Lomond Therapeutics, Inc. (the "Company") entered into a Termination Agreement with Bala Therapeutics, Inc. ("Bala"), pursuant to which that certain License Agreement, dated October 17, 2024, by and between the Company and Bala (the "License Agreement"), was terminated ab initio , effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1900520/000121390026003905/0001213900-26-003905-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.